3-Methylcrotonyl-CoA carboxylase deficiency

Jump to: navigation, search
3-Methylcrotonyl-CoA carboxylase deficiency
OMIM 210200
DiseasesDB 32207

WikiDoc Resources for 3-Methylcrotonyl-CoA carboxylase deficiency

Articles

Most recent articles on 3-Methylcrotonyl-CoA carboxylase deficiency

Most cited articles on 3-Methylcrotonyl-CoA carboxylase deficiency

Review articles on 3-Methylcrotonyl-CoA carboxylase deficiency

Articles on 3-Methylcrotonyl-CoA carboxylase deficiency in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on 3-Methylcrotonyl-CoA carboxylase deficiency

Images of 3-Methylcrotonyl-CoA carboxylase deficiency

Photos of 3-Methylcrotonyl-CoA carboxylase deficiency

Podcasts & MP3s on 3-Methylcrotonyl-CoA carboxylase deficiency

Videos on 3-Methylcrotonyl-CoA carboxylase deficiency

Evidence Based Medicine

Cochrane Collaboration on 3-Methylcrotonyl-CoA carboxylase deficiency

Bandolier on 3-Methylcrotonyl-CoA carboxylase deficiency

TRIP on 3-Methylcrotonyl-CoA carboxylase deficiency

Clinical Trials

Ongoing Trials on 3-Methylcrotonyl-CoA carboxylase deficiency at Clinical Trials.gov

Trial results on 3-Methylcrotonyl-CoA carboxylase deficiency

Clinical Trials on 3-Methylcrotonyl-CoA carboxylase deficiency at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on 3-Methylcrotonyl-CoA carboxylase deficiency

NICE Guidance on 3-Methylcrotonyl-CoA carboxylase deficiency

NHS PRODIGY Guidance

FDA on 3-Methylcrotonyl-CoA carboxylase deficiency

CDC on 3-Methylcrotonyl-CoA carboxylase deficiency

Books

Books on 3-Methylcrotonyl-CoA carboxylase deficiency

News

3-Methylcrotonyl-CoA carboxylase deficiency in the news

Be alerted to news on 3-Methylcrotonyl-CoA carboxylase deficiency

News trends on 3-Methylcrotonyl-CoA carboxylase deficiency

Commentary

Blogs on 3-Methylcrotonyl-CoA carboxylase deficiency

Definitions

Definitions of 3-Methylcrotonyl-CoA carboxylase deficiency

Patient Resources / Community

Patient resources on 3-Methylcrotonyl-CoA carboxylase deficiency

Discussion groups on 3-Methylcrotonyl-CoA carboxylase deficiency

Patient Handouts on 3-Methylcrotonyl-CoA carboxylase deficiency

Directions to Hospitals Treating 3-Methylcrotonyl-CoA carboxylase deficiency

Risk calculators and risk factors for 3-Methylcrotonyl-CoA carboxylase deficiency

Healthcare Provider Resources

Symptoms of 3-Methylcrotonyl-CoA carboxylase deficiency

Causes & Risk Factors for 3-Methylcrotonyl-CoA carboxylase deficiency

Diagnostic studies for 3-Methylcrotonyl-CoA carboxylase deficiency

Treatment of 3-Methylcrotonyl-CoA carboxylase deficiency

Continuing Medical Education (CME)

CME Programs on 3-Methylcrotonyl-CoA carboxylase deficiency

International

3-Methylcrotonyl-CoA carboxylase deficiency en Espanol

3-Methylcrotonyl-CoA carboxylase deficiency en Francais

Business

3-Methylcrotonyl-CoA carboxylase deficiency in the Marketplace

Patents on 3-Methylcrotonyl-CoA carboxylase deficiency

Experimental / Informatics

List of terms related to 3-Methylcrotonyl-CoA carboxylase deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


3-Methylcrotonyl-CoA carboxylase deficiency (3MCC deficiency), also known as 3-Methylcrotonylglycinuria type 1 or BMCC deficiency is an inherited disorder in which the body is unable to process certain proteins properly. People with this disorder have inadequate levels of an enzyme that helps break down proteins containing the amino acid leucine. This condition affects an estimated 1 in 50,000 individuals worldwide.

Presentation

Infants with this disorder appear normal at birth but usually develop signs and symptoms during the first year of life or in early childhood. The characteristic features of this condition, which can range from mild to life-threatening, include feeding difficulties, recurrent episodes of vomiting and diarrhea, excessive tiredness (lethargy), and weak muscle tone (hypotonia). If untreated, this disorder can lead to delayed development, seizures, and coma. Early detection and lifelong management (following a low-protein diet and using appropriate supplements) may prevent many of these complications. In some cases, people with gene mutations that cause 3-methylcrotonyl-CoA carboxylase deficiency never experience any signs or symptoms of the disorder.

The characteristic features of this condition are similar to those of Reye syndrome, a severe disorder that develops in children while they appear to be recovering from viral infections such as chicken pox or flu. Most cases of Reye syndrome are associated with the use of aspirin during these viral infections.

Genetics

The MCCC1 and MCCC2 genes make protein subunits that come together to form an enzyme called 3-methylcrotonyl-CoA carboxylase. This enzyme plays an essential role in breaking down proteins from the diet. Specifically, the enzyme is responsible for the fourth step in processing leucine. If a mutation in the MCCC1 or MCCC2 gene reduces or eliminates the activity of 3-methylcrotonyl-CoA carboxylase, the body is unable to process leucine properly. As a result, toxic byproducts of leucine processing build up to harmful levels, damaging the brain and nervous system. This condition is inherited in an autosomal recessive pattern.

Screening

It is one of the 29 conditions currently recommended for newborn screening by the American College of Medical Genetics.

References

This article incorporates public domain text from The U.S. National Library of Medicine

External links



Linked-in.jpg